Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases

Fineline Cube Dec 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial

Fineline Cube Dec 24, 2024

China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...

Company Drug

AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC

Fineline Cube Dec 24, 2024

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...

Company Deals

Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’

Fineline Cube Dec 24, 2024

US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...

Company Deals

Sanofi and SK bioscience Broaden Partnership to Develop Next-Gen Pneumococcal Vaccines

Fineline Cube Dec 24, 2024

French pharmaceutical major Sanofi (NASDAQ: SNY) and South Korea-based SK bioscience (KRX: 302440) have announced...

Company Deals

Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage

Fineline Cube Dec 24, 2024

China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...

Company Drug

ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors

Fineline Cube Dec 24, 2024

China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC

Fineline Cube Dec 24, 2024

Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...

Company Drug

Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment

Fineline Cube Dec 24, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from...

Company

BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”

Fineline Cube Dec 24, 2024

China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...

Company Deals

RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904

Fineline Cube Dec 24, 2024

US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...

Company Deals

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development

Fineline Cube Dec 24, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic...

Company Drug

GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial

Fineline Cube Dec 23, 2024

UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44...

Company Drug

Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment

Fineline Cube Dec 23, 2024

US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...

Company Drug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

Fineline Cube Dec 23, 2024

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...

Company Drug

Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis

Fineline Cube Dec 23, 2024

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration...

Company

Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District

Fineline Cube Dec 23, 2024

On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen....

Company Drug

CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009

Fineline Cube Dec 23, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced the clinical filing for its CS2009, a PD-1/VEGF/CTLA-4...

Company Medical Device

Becton, Dickinson and Co. Launches RMB1.332 Billion Factory in Jiangsu for Pre-Filled Syringes

Fineline Cube Dec 23, 2024

US-based Becton, Dickinson and Co., (BD) has officially put into operation its new factory in...

Company Deals

C.Q. Pharmaceutical Holding to Come Under SASAC’s Indirect Control via Genertec Acquisition

Fineline Cube Dec 23, 2024

C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a Chongqing-based pharmaceutical company, is set to be...

Posts pagination

1 … 283 284 285 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.